CU24643B1 - Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 - Google Patents
Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47Info
- Publication number
- CU24643B1 CU24643B1 CU2020000046A CU20200046A CU24643B1 CU 24643 B1 CU24643 B1 CU 24643B1 CU 2020000046 A CU2020000046 A CU 2020000046A CU 20200046 A CU20200046 A CU 20200046A CU 24643 B1 CU24643 B1 CU 24643B1
- Authority
- CU
- Cuba
- Prior art keywords
- inhibitors
- signaling pathways
- oxadiazole compounds
- compounds
- formula
- Prior art date
Links
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 title abstract 3
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 title abstract 3
- 230000019491 signal transduction Effects 0.000 title abstract 2
- 150000005071 1,2,4-oxadiazoles Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<p>La presente invención se refiere a compuestos de fórmula (1),</p> <p>ESPACIO PARA FÓRMULA</p> <p>que inhiben la vía de señalización de CD47 y sus composiciones. Estos compuestos son útiles para tratar enfermedades de trastornos mediados por CD47.</p>
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN201841001438 | 2018-01-12 | ||
| PCT/IB2019/050219 WO2019138367A1 (en) | 2018-01-12 | 2019-01-11 | 1,2,4-oxadiazole compounds as inhibitors of cd47 signalling pathways |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20200046A7 CU20200046A7 (es) | 2021-03-11 |
| CU24643B1 true CU24643B1 (es) | 2023-02-13 |
Family
ID=67213573
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CU2020000046A CU24643B1 (es) | 2018-01-12 | 2019-01-11 | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US11274123B2 (es) |
| EP (1) | EP3737401A4 (es) |
| JP (2) | JP7438955B2 (es) |
| KR (1) | KR20200108846A (es) |
| CN (1) | CN111601801A (es) |
| AU (2) | AU2019206438B2 (es) |
| BR (1) | BR112020014202A2 (es) |
| CA (1) | CA3087841A1 (es) |
| CU (1) | CU24643B1 (es) |
| EA (1) | EA202091267A1 (es) |
| IL (1) | IL275952A (es) |
| MX (1) | MX2020007383A (es) |
| PH (1) | PH12020551062A1 (es) |
| SG (1) | SG11202005992XA (es) |
| WO (1) | WO2019138367A1 (es) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022507025A (ja) * | 2018-11-08 | 2022-01-18 | オーリジーン ディスカバリー テクノロジーズ リミテッド | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
| AU2020315598A1 (en) | 2019-07-16 | 2022-03-03 | Gilead Sciences, Inc. | HIV vaccines and methods of making and using |
| KR20220085796A (ko) | 2019-10-18 | 2022-06-22 | 포티 세븐, 인코포레이티드 | 골수이형성 증후군 및 급성 골수성 백혈병을 치료하기 위한 조합 치료 |
| US20210147568A1 (en) | 2019-10-31 | 2021-05-20 | Forty Seven, Inc. | Anti-cd47 based treatment of blood cancer |
| EP4081305B1 (en) | 2019-12-24 | 2024-09-18 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN115087488A (zh) | 2020-02-14 | 2022-09-20 | 震动疗法股份有限公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| CA3172449A1 (en) | 2020-03-27 | 2021-09-30 | Erik Hans MANTING | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| KR20230157388A (ko) | 2021-03-12 | 2023-11-16 | 멘두스 비.브이. | 백신접종의 방법 및 cd47 차단의 용도 |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| KR20240025616A (ko) | 2021-06-23 | 2024-02-27 | 길리애드 사이언시즈, 인코포레이티드 | 다이아실글리세롤 키나제 조절 화합물 |
| AU2022297367A1 (en) | 2021-06-23 | 2023-12-07 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359411A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR102690136B1 (ko) * | 2021-06-30 | 2024-07-31 | 연세대학교 산학협력단 | 바이러스 및 박테리아의 중복 감염 치료용 조성물 |
| KR20240091056A (ko) | 2021-10-28 | 2024-06-21 | 길리애드 사이언시즈, 인코포레이티드 | 피리디진-3(2h)-온 유도체 |
| CN118201941A (zh) | 2021-10-29 | 2024-06-14 | 吉利德科学公司 | Cd73化合物 |
| CA3239528A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| US20240116928A1 (en) | 2022-07-01 | 2024-04-11 | Gilead Sciences, Inc. | Cd73 compounds |
| WO2024015741A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| US20240091351A1 (en) | 2022-09-21 | 2024-03-21 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024137852A1 (en) | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0230045D0 (en) * | 2002-12-23 | 2003-01-29 | Glaxo Group Ltd | Compounds |
| CA2641734A1 (en) * | 2006-02-15 | 2007-08-23 | Abbott Laboratories | Acetyl-coa carboxylase (acc) inhibitors and their use in diabetes, obesity and metabolic syndrome |
| PL3789038T3 (pl) | 2010-05-14 | 2023-01-23 | The Board Of Trustees Of The Leland Stanford Junior University | Humanizowane i chimeryczne przeciwciała monoklonalne wobec cd47 |
| ES2788848T3 (es) | 2013-09-06 | 2020-10-23 | Aurigene Discovery Tech Ltd | Derivados de 1,2,4-oxadiazol como inmunomoduladores |
| ITTO20130731A1 (it) | 2013-09-09 | 2015-03-10 | Indesit Co Spa | Muffola di un forno nella quale sono fissate delle guide |
| MX2017011614A (es) | 2015-03-10 | 2018-03-23 | Aurigene Discovery Tech Ltd | Compuestos de 1,3,4-oxadiazol y tiadiazol como inmunomoduladores. |
| JP2018507894A (ja) * | 2015-03-10 | 2018-03-22 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | 免疫調節剤としての３−置換−１，２，４−オキサジアゾールおよびチアジアゾール化合物 |
| CU24509B1 (es) * | 2015-03-10 | 2021-05-12 | Aurigene Discovery Tech Ltd | Compuestos de 1,2,4-oxadiazol y tiadiazol como inmunomoduladores |
| CN104804093A (zh) | 2015-05-27 | 2015-07-29 | 江苏春申堂药业有限公司 | 一种针对cd47的单域抗体 |
| GB2558131B (en) | 2015-09-21 | 2021-05-19 | Surface Oncology Inc | Anti-CD47 antibodies and methods of use |
| CA3048193A1 (en) * | 2015-12-23 | 2017-06-29 | Moonshot Pharma Llc | Methods for inducing an immune response by promoting premature termination codon read-through |
| EP3243522A1 (en) | 2016-05-10 | 2017-11-15 | Université Pierre et Marie Curie (Paris 6) | Agonist agents of cd47 inducing programmed cell death and their use in the treatments of diseases associated with defects in programmed cell death |
| ES2908729T3 (es) | 2016-05-10 | 2022-05-03 | Inst Nat Sante Rech Med | Nuevos compuestos y uso farmacéutico de los mismos en el tratamiento del cáncer |
| JP2022507025A (ja) * | 2018-11-08 | 2022-01-18 | オーリジーン ディスカバリー テクノロジーズ リミテッド | 小分子ｃｄ－４７阻害剤の他の抗癌剤との組み合わせ |
-
2019
- 2019-01-11 CA CA3087841A patent/CA3087841A1/en active Pending
- 2019-01-11 CU CU2020000046A patent/CU24643B1/es unknown
- 2019-01-11 KR KR1020207020398A patent/KR20200108846A/ko not_active Application Discontinuation
- 2019-01-11 AU AU2019206438A patent/AU2019206438B2/en active Active
- 2019-01-11 EP EP19738566.9A patent/EP3737401A4/en active Pending
- 2019-01-11 BR BR112020014202-6A patent/BR112020014202A2/pt unknown
- 2019-01-11 US US16/245,860 patent/US11274123B2/en active Active
- 2019-01-11 SG SG11202005992XA patent/SG11202005992XA/en unknown
- 2019-01-11 JP JP2020538785A patent/JP7438955B2/ja active Active
- 2019-01-11 WO PCT/IB2019/050219 patent/WO2019138367A1/en active Application Filing
- 2019-01-11 EA EA202091267A patent/EA202091267A1/ru unknown
- 2019-01-11 CN CN201980007859.6A patent/CN111601801A/zh active Pending
- 2019-01-11 MX MX2020007383A patent/MX2020007383A/es unknown
-
2020
- 2020-07-09 IL IL275952A patent/IL275952A/en unknown
- 2020-07-10 PH PH12020551062A patent/PH12020551062A1/en unknown
-
2021
- 2021-01-22 US US17/155,242 patent/US11560403B2/en active Active
-
2023
- 2023-01-05 US US18/150,246 patent/US20230144653A1/en active Pending
- 2023-12-14 JP JP2023211350A patent/JP2024028989A/ja active Pending
-
2024
- 2024-03-04 AU AU2024201411A patent/AU2024201411A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020007383A (es) | 2020-10-12 |
| AU2024201411A1 (en) | 2024-03-21 |
| PH12020551062A1 (en) | 2021-09-01 |
| JP2021514345A (ja) | 2021-06-10 |
| US20210139536A1 (en) | 2021-05-13 |
| AU2019206438B2 (en) | 2023-12-07 |
| US20230144653A1 (en) | 2023-05-11 |
| US11560403B2 (en) | 2023-01-24 |
| WO2019138367A1 (en) | 2019-07-18 |
| IL275952A (en) | 2020-08-31 |
| JP2024028989A (ja) | 2024-03-05 |
| CN111601801A (zh) | 2020-08-28 |
| AU2019206438A1 (en) | 2020-07-02 |
| EP3737401A1 (en) | 2020-11-18 |
| JP7438955B2 (ja) | 2024-02-27 |
| US11274123B2 (en) | 2022-03-15 |
| CA3087841A1 (en) | 2019-07-18 |
| US20190218252A1 (en) | 2019-07-18 |
| EP3737401A4 (en) | 2021-09-15 |
| SG11202005992XA (en) | 2020-07-29 |
| EA202091267A1 (ru) | 2020-11-03 |
| BR112020014202A2 (pt) | 2020-12-01 |
| CU20200046A7 (es) | 2021-03-11 |
| KR20200108846A (ko) | 2020-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24643B1 (es) | Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47 | |
| CU20190003A7 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| CL2017002606A1 (es) | Inhibidor de bromodominio | |
| CL2020001931A1 (es) | Compuestos para el tratamiento de trastornos dependientes de cinasas. | |
| CO2018004964A2 (es) | Compuestos útiles como inmunomoduladores | |
| CL2018002505A1 (es) | Inhibidores del envejecimiento proteico-proteico wdr5 | |
| CU20210080A7 (es) | Triazinas sustituidas como inhibidores de proteína tirosina fosfatasa | |
| UY37134A (es) | Compuestos heteroarilos y composiciones que los contienen útiles como inhibidores de pad4 | |
| UY36705A (es) | Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj | |
| UY37169A (es) | Análogos de 1,4-dihidropirimidin-5-carboxamidas como agonistas de apj y composiciones que los contienen | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| PE20180451A1 (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
| UY31072A1 (es) | Imidazopiridazinas sustituidas como inhibidores de cinasa de lipido | |
| CU24395B1 (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
| CU20170026A7 (es) | Compuestos derivados de 2-(benzamido/picolinamido/nicotinamido/isonicotinamido)-(2-metil-6-morfolino-(fenil/ (3,4´-bipiridin))-2-il)oxi)etil dihidrógeno fosfato como inhibidores de quinasa raf | |
| CL2011002726A1 (es) | Compuestos derivados de sulfonamidas, sus n-oxidos y sus sales; composicion que los comprende; metodo para controlar un nematodo parasitico y semilla tratada. | |
| CR20160321A (es) | Modulares de tetrahidropiridopirazinas de gpr6 | |
| CL2020000375A1 (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre. | |
| CL2021001461A1 (es) | Moduladores de trex1 | |
| CU23824A3 (es) | Compuestos tricíclicos y sus composiciones | |
| CU20190069A7 (es) | Compuestos químicos derivados sustituidos de 1h-pirrolo[2,3-b] piridina como moduladores del receptor de hidrocarburos de arilo (ahr) | |
| DOP2017000120A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| CL2017002745A1 (es) | Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas | |
| CL2018003377A1 (es) | Compuestos novedosos para tratar enfermedades parasitarias. (divisional solicitud 201803187) | |
| CL2021001198A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina |